Redx income rises to £2.8m

Redx Pharma is expecting its total income for the financial year ended September 30 to be £2.8m. The Liverpool and Alderley Park-based firm is reporting good progress over the second half of the financial year with expenditure in line with budgets and income growing from £2m in the first six months to March 31.

Redx, which several weeks ago announced a cancer research collaboration with international life science group Horizon Discovery Group to develop a pan-RAF inhibitor programme for colorectal cancer – the fourth most common cancer and the second most cause of deal from the disease in the UK – is in “encouraging discussions” over further commercial collaborations.

See article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.